Medical Corps (United States Army)

American Vision Partners Welcomes Dr. Shaun Brierly as new Chief Medical Officer

Retrieved on: 
Wednesday, January 18, 2023
Business administration, Master of Business Administration, Operation Inherent Resolve, Medical director, University, Bachelor of Science in Human Biology, OR, Internal medicine, Optometry, American Board of Commissioners for Foreign Missions, Cal Poly, Doctor of Medicine, Medicine, Medical corps, Ross School of Business, Audiology, Marine biology, Medical Corps (United States Army), Imaging, Patient, General surgery, University of Michigan, American Board of Ophthalmology, St. Vincent Hospital, Kaiser Permanente, Specialty, AVP, Business, UC Davis Medical Center, Management, Sonoma Magazine, Dermatology, Ophthalmology, PHOENIX, Science, Podiatry

PHOENIX, Jan. 18, 2023 /PRNewswire-PRWeb/ -- American Vision Partners ("AVP"), one of the largest and fastest-growing eye care management organizations in the nation, announced the hire of Dr. Shaun Brierly, M.D. as their new Chief Medical Officer.

Key Points: 
  • American Vision Partners ("AVP"), one of the largest and fastest-growing eye care management organizations in the nation, announced the hire of Dr. Shaun Brierly, M.D.
  • PHOENIX, Jan. 18, 2023 /PRNewswire-PRWeb/ -- American Vision Partners ("AVP"), one of the largest and fastest-growing eye care management organizations in the nation, announced the hire of Dr. Shaun Brierly, M.D.
  • Dr. Brierly also comes to American Vision Partners with more than two decades of experience developing his clinical and leadership skills across diverse environments.
  • "We are extremely fortunate to have a clinical leader of Dr. Brierly's caliber," said Shane Armstrong, CEO of American Vision Partners.

Profound Medical Announces Changes to its Commercial Organization to Support Continued Growth

Retrieved on: 
Thursday, September 15, 2022
Urethra, Bone, DePuy, Industry, Phrase, Hematuria, Health Canada, Louisiana State University, Technology, BS, Medical Corps (United States Army), Indian Medical Association, NASDAQ, United Nations Convention on Contracts for the International Sale of Goods, BPH, Adoption, VP, Food, AG, National Medical Products Administration, Brainlab, Company, Growth, MBA, CE, Biology, FDA, Humanitarian Device Exemption, Uterine fibroid, Medtronic, American Medical Association, GLOBE, TSX, Biological engineering, Prostate, MRI, Rectum, Regulation of tobacco by the U.S. Food and Drug Administration, Risk, Hyperthermia, Prostate cancer, Covidien, Pharmaceutical industry, IMRIS, Profound Pharma, Boston Scientific

At the same time, we are excited that he is leaving our commercial organization in such good hands.

Key Points: 
  • At the same time, we are excited that he is leaving our commercial organization in such good hands.
  • Ms. Goodman brings over 17 years of medical device sales experience, most recently serving as Profounds VP, U.S.
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.

Profound Medical Provides TULSA-PRO® Reimbursement Update

Retrieved on: 
Friday, September 2, 2022
Phrase, Bone, CEO, Technology, Centers for Medicare & Medicaid Services, Current, Urethra, Regulation of tobacco by the U.S. Food and Drug Administration, OPPS, NASDAQ, Calendar, National Medical Products Administration, Category 1, CMS, Risk, Food, Hyperthermia, Rectum, Current Procedural Terminology, Health Canada, TSX, Hospital, BPH, GLOBE, Humanitarian Device Exemption, Medicare, CPT, FDA, Company, Hematuria, MRI, Uterine fibroid, Prostate cancer, Medical Corps (United States Army), CE, Growth, Adoption, Patient, Medical imaging, Health insurance, Pharmaceutical industry, Profound Pharma

TORONTO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today provided a U.S. reimbursement update for Transurethral Ultrasound Ablation (TULSA), performed with its TULSA-PRO system.

Key Points: 
  • TORONTO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today provided a U.S. reimbursement update for Transurethral Ultrasound Ablation (TULSA), performed with its TULSA-PRO system.
  • Profound anticipates that an updated application, which will include 2022 utilization data, will be submitted at the appropriate time in 2023.
  • In July 2022, CMS released its proposed OPPS reimbursement rule for calendar year 2023.
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Artax Biopharma Appoints D. Scott Batty, Jr., M.D. as Chief Medical Officer

Retrieved on: 
Wednesday, June 29, 2022
Tufts University School of Medicine, National, Health, View, Patient, Artax, Bureau of Oceans and International Environmental and Scientific Affairs, Medical Corps (United States Army), CEO, Liver transplantation, National Institute, MedStar Georgetown University Hospital, Walter Reed Army Medical Center, Therapure BioPharma Inc, Behavior, Immunosuppression, Medical Affairs Bureau, CTI, Company, Industry, TCR, Degenerative disease, NIH, CMO, Tcell, Immune system, National Institute of Diabetes and Digestive and Kidney Diseases, Risk, Lymphoma, Regulation, Kidney, NIDDK, University, Autoimmune disease, Digestive, Immunomodulation, Infection, Leadership, Lieutenant colonel, Children's Oncology Group, Bristol Myers Squibb, Multimedia, Organ, Transplant, Vaccine, Dentistry, NCK

CAMBRIDGE, Mass., June 29, 2022 /PRNewswire/ -- Artax Biopharma, Inc., a clinical stage biotechnology company focused on transforming the treatment of T Cell-mediated diseases, today announces the appointment of D. Scott Batty, Jr., M.D. as Chief Medical Officer. Dr. Batty will direct the Company's scientific and clinical research programs, including Artax's ongoing Phase 1 clinical trial evaluating AX-158, the Company's first-in-class, oral small molecule immunomodulating agent that selectively modulates inappropriate T cell activation, a known cause of autoimmune disease. Importantly, AX-158 has the potential to treat T Cell-mediated diseases without the risk of immunosuppression.

Key Points: 
  • Prior to joining Artax, Dr. Batty was VP of Regulatory and Scientific Affairs for CTI, Inc., a privately held contract research organization.
  • Previous roles included Chief Medical Officer at Medeor Therapeutics, which developed an organ transplantation cell therapy platform to avoid the use of pharmacologic immunosuppression; Chief Executive Officer of ImmunArray Ltd., and Vice President of Global Medical Affairs for Genzyme Transplant and Oncology Group.
  • Dr. Batty was also a Global Director of Medical Affairs for the belatacept immunosuppression program while at Bristol-Myers Squibb.
  • Artax Biopharma is a clinical-stage biotechnology company transforming TCell-mediated disease treatment by developing innovative small molecules that modulate the immune system.

Blueberries Medical Reports 2022 Q1 Financial Results and Provides Corporate and Operations Update

Retrieved on: 
Monday, May 30, 2022
Income, Company, Food, Patient, Mission statement, OTC, Solution, BBM, Association, US, Cannabinoid, CBG, CSE, Genetics, Industry, GACP, Time, Cannabis industry, Partnership, CBN, Pittsburgh Food & Beverage Company, Board, FMCG in India, CAPEX, Flower, Operate, Colombian Association of Actuaries, B2B, THC, Connect, Drink, FRA, Medical Corps (United States Army), CFO, CEO, Pharmacy, GLOBE, Coffee, Airline, Drug, CBD, Blueberry, Excellence, Cannabis, Differentiation

TORONTO, May 30, 2022 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA), the Canadian parent of Blueberries S.A.S.

Key Points: 
  • TORONTO, May 30, 2022 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA), the Canadian parent of Blueberries S.A.S.
  • Today, Blueberries has filed its unaudited condensed interim consolidated financial statements and related management's discussion and analysis, both of which are available on Blueberries profile at www.sedar.com .
  • Blueberries Medical Corp. continues deploying the strategy of reducing administrative cost, capital and operational expenditures, as well as focusing on multiple revenue-generating activities.
  • We are really thrilled with this new business opportunities, said Facundo Garreton, Chief Executive Officer and Chairman of Blueberries Medical Corp.

TULSA-PRO® Was Front and Center at AUA2022

Retrieved on: 
Tuesday, May 17, 2022
Department, Physician, Education, Software, University of Texas Southwestern Medical Center, Company, Annual general meeting, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Uterine fibroid, Hyperthermia, American Urological Association, Hematuria, National Medical Products Administration, Susceptibility weighted imaging, Patient, MRI, SWI, NASDAQ, ADC, BPH, Bone, Quality of life, Prostate, AMA, Benign prostatic hyperplasia, CE, Trial of the century, TSX, Humanitarian Device Exemption, DWI, FDA, Urology, Prostate cancer, AUA, Man, University, Technology, Risk, LUTS, Rectum, Diffusion, Health Canada, Plenary session, Turku University, Phrase, Growth, Urethra, Medical Corps (United States Army), GLOBE, Medical imaging, Pharmaceutical industry, Profound Pharma

Of particular note, Kenneth A. Goldberg, M.D., an Assistant Professor in the Department of Urology at UT Southwestern Medical Center, performed a Semi-Live TULSA Procedure during the afternoon Plenary Session on May 13th.

Key Points: 
  • Of particular note, Kenneth A. Goldberg, M.D., an Assistant Professor in the Department of Urology at UT Southwestern Medical Center, performed a Semi-Live TULSA Procedure during the afternoon Plenary Session on May 13th.
  • We are extremely encouraged by the positive feedback we received at this event, which adds to the momentum of Profounds ongoing commercialization strategy for TULSA-PRO.
  • The study reported 6-month improvement in patient quality of life, LUTS, sexual function and uroflowmetry, with all men discontinuing their BPH medication.
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Blueberries Medical Reports 2021 Q3 Financial Results and Provides Corporate and Operations Update

Retrieved on: 
Monday, November 29, 2021
Patient, Sale, Medical Corps (United States Army), Seed, Connect, Industry, Time, BBM, Trade and Investment Framework Agreement, Pittsburgh Food & Beverage Company, Company, Income, Impact of the COVID-19 pandemic on the cannabis industry, Partnership, THC, Operate, Mission statement, CAPEX, CBD, Solution, FRA, CSE, Framework agreement, Genetics, GLOBE, FMCG in India, Association, Drink, Board, OTC, Director, Framework, Differentiation, Colombian Association of Actuaries, B2B, Food, Pharmacy, Jet fuel, Drug, Risk management

TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA), the Canadian parent of Blueberries S.A.S.

Key Points: 
  • TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA), the Canadian parent of Blueberries S.A.S.
  • (BBSAS), the premier Latin American licensed cultivator and producer of medicinal cannabis and medicinal-grade cannabis extracts, (together the Company or "Blueberries"), is pleased to report its financial results for the quarter ended September 30, 2021.
  • Today, Blueberries has filed its unaudited condensed interim consolidated financial statements and related management's discussion and analysis, both of which are available on Blueberries profile at www.sedar.com .
  • Blueberries Medical Corp. continues deploying the strategy of reducing administrative cost, capital and operational expenditures, as well as focusing on multiple revenue-generating activities.

Profound Medical Announces Third Quarter 2021 Financial Results

Retrieved on: 
Thursday, November 4, 2021
G&A, Webcast, International Financial Reporting Standards, Investor, Consultant, BPH, Hematuria, Prostate cancer, Health Canada, NASDAQ, Medical Corps (United States Army), Technology, Rectum, International Accounting Standards Committee, Food, Hyperthermia, Insurance, CE, Risk, Growth, Phrase, COVID-19, Medtech, International, Research, Regulation of tobacco by the U.S. Food and Drug Administration, MRI, Sale, National Medical Products Administration, TSX, Urethra, Humanitarian Device Exemption, Conference, Company, International Accounting Standards Board, GLOBE, Prostate, Bone, Patient, FDA, Uterine fibroid, Pharmaceutical industry, Cryptocurrency, Animal

TORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the third quarter ended September 30, 2021.

Key Points: 
  • TORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the third quarter ended September 30, 2021.
  • Third quarter 2021 selling and distribution expenses increased by 72% to approximately $2.0 million, compared with $1.2 million in the third quarter of 2020.
  • For complete financial results, please see Profounds filings at www.sedar.com , www.sec.gov and on the Companys website at www.profoundmedical.com under Financial in the Investors section.
  • Profound Medical is pleased to invite all interested parties to participate in a conference call today, November 4, 2021, at 4:30 pm ET during which time the results will be discussed.

Blueberries Medical Announces that its wholly subsidiary Blueberries SAS at Bogota, Colombia has made one of the biggest exports of Premium CBD Full Spectrum Oil of all time, scaling up its business to a level that will improve life condition of more than

Retrieved on: 
Monday, October 4, 2021
THC, GMP, Goal, News, Insurance, General Directorate of Mapping, USD, Efficiency, OTC, Risk, Sale, Private placement, CSE, Patient, SAS, Certification, Board, Private, Medical Corps (United States Army), BBM, Phrase, Marketing, Corporation, FRA, Medicine, Company, Legislation, Agriculture, Farm, Pharmacology, No, SEDAR, Genetics, Cannabis, Corporate finance, Time, GLOBE, Drug, Risk management

This is the Companys largest sale to any customer worldwide since the beginning of the operations in 2018.

Key Points: 
  • This is the Companys largest sale to any customer worldwide since the beginning of the operations in 2018.
  • Given the size of the shipment, the Company estimates that approximately 2.500 patients will benefit from the resultant finished formulas.
  • In that sense, Company expects generate more than 7x revenues in comparison with previous fiscal year.
  • No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Blueberries Medical Announces Closing of C$ 2.1 Million Non-Brokered Private Placement and the Appointment of New Director

Retrieved on: 
Thursday, September 9, 2021

The seed funding round was led by FLA Ventures (FLA) (a current shareholder of Blueberries), MPE Investments and Yaax Capital.

Key Points: 
  • The seed funding round was led by FLA Ventures (FLA) (a current shareholder of Blueberries), MPE Investments and Yaax Capital.
  • Terraflos is currently considering various opportunities in Argentina, Mexico and Brazil, and aims to expand its operations into those markets in the short term.
  • The Company is also pleased to announce the appointment of Joaquin Barbera as a new independent member of the board of directors of the Company.
  • Joaqun studied business strategy at Harvard University and at the IAE Business School and he is a specialist in innovation and sustainability.